Cover Image

Patient enrollment per month (accrual) in clinical trials leading to the FDA approval of new cancer drugs

Insufficient patient enrollment per month (=accrual) is the leading cause of cancer trial termination.

Saved in:
Bibliographic Details
Main Authors: Michaeli, Daniel (Author) , Michaeli, Christoph T. (Author) , Albers, Sebastian (Author) , Michaeli, Julia (Author)
Format: Article (Journal)
Language:English
Published: September 2024
In: Targeted oncology
Year: 2024, Volume: 19, Issue: 5, Pages: 797-809
ISSN:1776-260X
DOI:10.1007/s11523-024-01081-w
Online Access:Verlag, kostenfrei, Volltext: https://doi.org/10.1007/s11523-024-01081-w
Verlag, kostenfrei, Volltext: https://link.springer.com/article/10.1007/s11523-024-01081-w
Get full text
Author Notes:Daniel Tobias Michaeli, Thomas Michaeli, Sebastian Albers, Julia Caroline Michaeli
Description
Summary:Insufficient patient enrollment per month (=accrual) is the leading cause of cancer trial termination.
Item Description:Online veröffentlicht: 31. Juli 2024
Gesehen am 28.10.2024
Physical Description:Online Resource
ISSN:1776-260X
DOI:10.1007/s11523-024-01081-w

Similar Items